MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company developing artificial intelligence-driven voice analytics for drug and alcohol intoxication detection, has completed manufacturing of its next-generation Edge AI Intoxication Detection Kiosk. The announcement signals a significant step toward commercializing a technology that could fundamentally change how workplaces screen for impairment.
The new hardware builds on a prototype developed in June and is designed to support the company’s proprietary Voice AI technology, which analyzes vocal characteristics to identify potential impairment. MindBio is now continuing software integration, system testing and validation of its predictive models against conventional breath alcohol and oral fluid testing methods. A potential initial commercial pilot is targeted for later this year.
Why does this matter? Conventional drug and alcohol screening is often invasive, time-consuming and costly, requiring trained personnel, specialized equipment and significant administrative overhead. MindBio’s kiosk aims to provide a rapid, non-invasive alternative that could enable more frequent, large-scale workplace screening while potentially reducing testing costs, administration time and operational disruptions.
The implications for safety-sensitive industries are substantial. Mining, aviation, construction, heavy transport and law enforcement all rely on robust impairment detection to protect workers and the public. Current testing protocols can be logistically challenging, especially when frequent checks are needed. A voice-based kiosk that delivers fast, accurate results could allow employers to test more often without major workflow interruptions, potentially catching impairment earlier and preventing accidents.
MindBio’s AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform that integrates bespoke hardware and software for detection in a range of environments, including the mining industry, aviation, construction and law enforcement. The planned commercial pilot would provide an opportunity to evaluate the technology’s performance in a real-world environment against existing testing methods, a critical step before broader adoption.
For investors, the completion of manufacturing and the prospect of a pilot later this year represent tangible progress. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://nnw.fm/MBQIF. The full press release can be viewed at https://nnw.fm/15cJf.
The announcement was disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. The company is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis, positioning itself at the intersection of artificial intelligence and workplace safety.
As the pilot approaches, the key question is whether voice-based intoxication detection can match the reliability of established methods in real-world conditions. If successful, MindBio’s kiosk could offer a scalable solution for industries where impairment poses serious risks, potentially setting a new standard for workplace screening. The technology’s non-invasive nature may also reduce resistance to testing and encourage more consistent compliance.
For more information about the company, visit MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF). The press release was distributed by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions via InvestorWire and other services. Please see full terms of use and disclaimers on the NetworkNewsWire website: https://www.NetworkNewsWire.com/Disclaimer.
